we discuss two decisions involving claims under Section 10b of the Securities Exchange Act of 1934 and Rule 10b-5 based on alleged channel stuffing a company’s practice of shipping excessive product to its distributors, and an allegedly over-hyped COVID-19 vaccine candidate.